{
    "clinical_study": {
        "@rank": "1586", 
        "arm_group": {
            "arm_group_label": "Induction Chemotherapy DCF followed by Surgery", 
            "arm_group_type": "Experimental", 
            "description": "All eligible patients will receive ND-420, Cisplatin and fluorouracil every 3 weeks for 2 cycles. After induction chemotherapy, patients will be planned to receive Surgery."
        }, 
        "brief_summary": {
            "textblock": "Investigator will assign 53 patients who had been histologically proven localized squamous\n      cell carcinoma of esophagus to receive the induction chemotherapy regimen of ND-420 50 mg/m2\n      on day 1, cisplatin 70 mg/m2 on day1, plus fluorouracil 700 mg/m2 daily, day1 to day4, every\n      3 weeks for 2 cycles and then followed by surgical resection. The successful rate of\n      complete treatment per protocol and complete resection will be the primary variant to\n      evaluate in our study."
        }, 
        "brief_title": "A Phase II Trial of Induction Chemotherapy With ND-420, Cisplatin and Fluorouracil Followed by Surgery in the Treatment of Patients With Localized Squamous Cell Carcinoma of the Esophagus", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Localized Squamous Cell Carcinoma of the Esophagus", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Squamous Cell", 
                "Esophageal Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients must have been histologically proven esophageal carcinoma (squamous cell\n             carcinoma).\n\n          -  The tumor had to be locally advanced (stage T2-3/N0, T1-3/N+, if technically\n             resectable with curative intent).\n\n          -  Patients must be 20 years of age.\n\n          -  Patients must have an ECOG performance status score 2.\n\n          -  Patients must have a life expectancy of at least 12 weeks.\n\n          -  Patients must be accessible for treatment and follow-up at least for one year.\n\n          -  Patients must sign the informed consent form.\n\n          -  Patient must have:Hemoglobin level 9 g/dl; Neutrophil count 1,500/mm3; Platelets\n             count 100,000/mm3; Serum bilirubin level 1.0 ULN; Serum transaminase (GOT, GPT)\n             levels 2.0 ULN; Serum Alkaline phosphatase levels 2.0 ULN; Serum creatinine level 1.5\n             mg/dl or Creatinine clearance rate(CrCl)60 ml/min for the institution (calculated by\n             the Cockcroft- Gault equation).\n\n        Exclusion Criteria:\n\n          -  Patient who are receiving or had received concurrent radiotherapy, chemotherapy or\n             other anticancer treatment for esophageal carcinoma.\n\n          -  Patients with known history of severe hypersensitivity reactions to any medicine or\n             to drugs formulated with polysorbate 80.\n\n          -  Major surgery within two weeks prior to entering the study, excluding port-A\n             insertion or feeding jejunostomy surgery.\n\n          -  Patients with CNS metastasis, including clinical suspicion.\n\n          -  Patients with clinically detectable peripheral neuropathy 2 on the CTC criteria.\n\n          -  Mental statuses of patients are not fit for clinical trial.\n\n          -  Fertile men and women unless using a reliable and appropriate contraceptive method.\n\n          -  Patients with pregnancy or lactating, women considering pregnancy, possible pregnancy\n             that without using effective contraception.\n\n          -  Patients who have serious concomitant illness that might be aggravated by\n             chemotherapy, as below included:Active cardiac disease (e.g. congestive heart\n             failure, angina, arrhythmia, acute myocardial disease or other types of heart disease\n             requiring treatment) within 6 months period preceding entry into the study;\n             Uncontrolled infection (e.g. active infection that uncontrolled for 2 weeks under\n             antibiotic therapy); Retention of body fluid (e.g. pleural effusion, ascites,\n             pericardial effusion, and edema needing treatment); History of other than esophageal\n             cancer, except curatively treated non-melanoma skin cancer or in situ carcinoma of\n             the esophagus; and other conditions which will be judged by physician's discretion."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02017600", 
            "org_study_id": "NKCND420/201112"
        }, 
        "intervention": [
            {
                "arm_group_label": "Induction Chemotherapy DCF followed by Surgery", 
                "description": "ND-420 50 mg/m2 on day1", 
                "intervention_name": "ND-420", 
                "intervention_type": "Drug", 
                "other_name": "ND-420(Nangkuang)"
            }, 
            {
                "arm_group_label": "Induction Chemotherapy DCF followed by Surgery", 
                "description": "After induction chemotherapy, participants will be receive right or left thoracotomy for curative resection by total or subtotal thoracic esophagectomy.", 
                "intervention_name": "Surgery", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "Induction Chemotherapy DCF followed by Surgery", 
                "description": "cisplatin 70 mg/m2 on day1", 
                "intervention_name": "Cisplatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Induction Chemotherapy DCF followed by Surgery", 
                "description": "fluorouracil 700 mg/m2 daily, day1 to day4", 
                "intervention_name": "fluorouracil", 
                "intervention_type": "Drug", 
                "other_name": "5-FU"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cisplatin", 
                "Fluorouracil"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 22, 2013", 
        "location": {
            "contact": {
                "email": "r98426006@ntu.edu.tw", 
                "last_name": "Shiang-yih Ho, Master", 
                "phone": "886-978661611"
            }, 
            "facility": {
                "address": {
                    "city": "Taipei", 
                    "country": "Taiwan", 
                    "zip": "112"
                }, 
                "name": "Taipei Veterans General Hospital"
            }, 
            "investigator": [
                {
                    "last_name": "Ming-Huang Chen, M.D.", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Chueh-chuan Yen, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Wen-Hu Hsu, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Yu-Chung Wu, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Chih-Cheng Hsieh, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Chien-Sheng Huang, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Po-Kuei Hsu, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Jung-Jyh Hung, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Sheng-Yu Chen, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Yu-Ming Liu, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Yi-Wei Chen, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Ko-Han Lin, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Mei-Han Wu, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Hsiao-Ping Chou, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Jiing-Chyuan Luo, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Teh-Ying Chou, M.D.", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Taiwan"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II Trial of Induction Chemotherapy With ND-420, Cisplatin and Fluorouracil Followed by Surgery in the Treatment of Patients With Localized Squamous Cell Carcinoma of the Esophagus", 
        "overall_official": {
            "affiliation": "Taipei Veterans General Hospital, Taiwan", 
            "last_name": "Ming-Huang Chen, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Taiwan : Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "the R0 resection rate of participants", 
            "safety_issue": "No", 
            "time_frame": "up to three months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02017600"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "the response rate (RECIST) of participants", 
                "safety_issue": "No", 
                "time_frame": "up to three months"
            }, 
            {
                "measure": "Number of participants with adverse events as a measure of safety and tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "up to one year"
            }, 
            {
                "measure": "the population pharmacokinetic parameters (Cmax, AUC... )of ND-420 in the participants", 
                "safety_issue": "No", 
                "time_frame": "0, 30min, 1hr of ND-420 infusion. selected randomly form one of 3hr, 7hr, 11hr and 23hr after the end of ND-420 infusion."
            }, 
            {
                "measure": "the correlation between clinical outcomes and the potential predictive genomic biomarkers(B-tubulin mutation, p53-Arg 72Pro, Bcl2-C938A, MDR1-C3435T polymorphism, TNFRSF1B-1466, GSTP1-l105V, CYP1B1, TS-5'UTR) for tumor response", 
                "safety_issue": "No", 
                "time_frame": "up to one year"
            }, 
            {
                "measure": "1-year survival rate of participants", 
                "safety_issue": "No", 
                "time_frame": "up to one year"
            }, 
            {
                "measure": "pathologic complete response rate of participants", 
                "safety_issue": "No", 
                "time_frame": "up to one year"
            }, 
            {
                "measure": "1-year progression free survival rate of participants", 
                "safety_issue": "No", 
                "time_frame": "up to one year"
            }, 
            {
                "measure": "1-year overall survival rate of participants", 
                "safety_issue": "No", 
                "time_frame": "up to one year"
            }
        ], 
        "source": "Nang Kuang Pharmaceutical Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Nang Kuang Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}